Breast Cancer and Fertility Preservation in Young Female Patients: A Systematic Review of the Literature.
Ioannis BoutasAdamantia KontogeorgiNektarios I KoufopoulosDionysios T DimasKyparissia SitaraSophia N KalantaridouConstantine DimitrakakisPublished in: Clinics and practice (2023)
The most suitable treatments for fertility preservation in young patients is the temporary suppression with luteinizing hormone-releasing analogs, while the patient undergoes chemotherapy and cryopreservation. For cryopreservation, the physicians might deem it necessary to either cryopreserve ovarian tissue taken from the patient before any treatment or cryopreserve embryos/oocytes. Cryopreservation of oocytes and/or embryos is the most effective solution for fertility preservation in women of reproductive age, who have a sufficient ovarian reserve and are diagnosed with breast cancer, regardless of the histological type of the tumor. Because approximately 50% of young breast cancer patients are interested in becoming pregnant right after completion of therapy, the evolution and development of fertility preservation techniques promise to be very exciting.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- primary care
- case report
- middle aged
- childhood cancer
- machine learning
- metabolic syndrome
- squamous cell carcinoma
- adipose tissue
- type diabetes
- pregnant women
- polycystic ovary syndrome
- artificial intelligence
- rectal cancer
- combination therapy